Initial Results From Phase I/Ii Study Of Arv-766 In Mcrpc

Initial results from Phase I/II Study of ARV-766 in mCRPC

The potential role of ARV-766, an oral PROTAC AR degrader, in mCRPC

Results of Phase I Study Reach Primary End Point for mCRPC

Targeted Oncology

PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC

GU Oncology Now

Results from a phase I study of AMG 160

European Association of Urology

A phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive mCRPC

PROPHECY trial: AR-V7 CTCs as a biomarker in mCRPC

A. Edward Yen - Prostate Cancer Highlights from GU ASCO and ASCO 2024

Grand Rounds in Urology

Phase I/II trial of BMS-986365 in mCRPC resistant to ARPIs

Prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging

How will the results of the SPARTAN study impact US clinical practice in prostate cancer?

Interim results from Phase II trial of atezolizumab and SBRT in cervical cancer

Phase 1 Trial of ARV-110 in Patients with mCRPC

Grand Rounds in Urology

PSMA-TRT, 225Ac-J591 and 177Lu-PSMA I&T in mCRPC

First-line treatments for patients with mHSPC and mCRPC

My Urologist suspected an infection PSA 5.06 Prostate V 6.5 cc M 58 year

Test Results Explained

VISION: safety analysis of 177Lu-PSMA-617 in mCRPC

Updated Phase I study results of PHE885 in patients with R/R multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Phase I/II trial of DEP cabazitaxel in esophagogastric cancers

Results of a Phase II Study of LHRH Therapy in High-Risk Prostate Cancer

Targeted Oncology